Clinical Trial Update: Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Open-label extension study of tofacitinib in psoriatic arthritis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Psoriatic | Phase 3 | Status: COMPLETED | Results posted: 2020-05-21